A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study will test whether CVL-562 (PF-06412562), a dopamine 1 partial agonist novel
compound, affects working memory neural circuits in patients with early episode
schizophrenia. The overall aim is to establish neuroimaging biomarkers of the Dopamine
Receptor 1/Dopamine Receptor 5 Family (D1R/D5R) target engagement to accelerate development
of D1R/D5R agonists in humans to treat cognitive impairments that underlie functional
disability in schizophrenia, a key unaddressed clinical and public health concern.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
Cerevel Therapeutics, LLC Columbia University State University of New York Stony Brook University of Pennsylvania